The National Comprehensive Cancer Network (NCCN) updates the "NCCN clinical practice guidelines in oncology: Lung cancer screening" annually, and the second edition of 2024 was released in October 2023. The 2024 edition of the guidelines builds on the 2023 edition with some updates on description and assessment of risk factors for lung cancer, evaluation and follow-up of lung nodules found during initial and subsequent screening, and low-dose CT screening protocols and imaging modalities. In this article, we will introduce the above updates and provide reference for lung cancer screening in China by combining the relevant guidelines and consensus in China.
ObjectiveTo interpret the intervention description and reporting standards (TIDieR), and further present the domestic and international application status of TIDieR based on knowledge graphs. And to provide references and inspirations for standardized reporting of intervention studies. MethodsTIDieR-related literature published in Chinese and English databases such as CNKI, WanFang Data, PubMed, and Web of Science was searched from 2014 to 2024, and visual analysis was conducted using CiteSpace6.3.R1 bibliometric software. ResultsTIDieR consisted of 12 entries, including abbreviated intervention name, implementation rationale, implementation materials, implementation process, implementer, implementation method, implementation site, implementation time and intensity, personalized plan, plan changes, expected effects, and actual effects. The bibliometric analysis included 94 English-language papers and 5 Chinese-language papers. The application of TIDieR was relatively widespread overseas, mainly involving health care, rehabilitation, and digital health fields. ConclusionTIDieR can ensure the standardization and reproducibility of intervention research reports. However, domestic scholars still apply TIDieR less frequently. It is necessary to gradually promote and strengthen the application of TIDieR in future intervention studies, thereby improving the transparency and quality of intervention research reports.
With the development of mobile technology and smartphones, the mobile health intervention project emerges, attracting grant fundings and creating new chances in healthcare. However, there is still few evidence to confirm the effectiveness of the mobile-health intervention, a possible cause being the lack of quality of research reporting, which needs to be improved for better identification, duplication and promotion of research projects. This paper interprets and analyses of the Consolidated Standards of Reporting Trials of Electronic and Mobile Health Application and onLine TeleHealth (CONSORT-EHEALTH), in an effort to provide a reference for conducting mobile health related controlled trials research.
On September 27, 2022, the first international standard of Diagnosis and Classification of Optic Neuritis was published online in Lancet Neurology, the top journal of neurology. The publication of this standard fills the gap in the international diagnosis and classification of optic neuritis (ON), promotes the consistency of the global diagnosis classification of ON, and helps ophthalmologists and neurologists to diagnose ON more accurately in the future. In recent decades, although Chinese ophthalmologists have made great progress in their understanding of ON and diagnosis and treatment level, it is still necessary to continue to strengthen the standardized training of Chinese neuro-ophthalmologist specialists, cooperate to establish a national ON clinical epidemiology database, carry out Chinese multi-center clinical studies, and further verify and optimize the international ON diagnostic system in future clinical practice. The ON diagnostic standards and treatment standards are gradually improved for China.
To enhance the quality and transparency of oncology real-world evidence studies, the European Society for Medical Oncology (ESMO) has developed the first specific reporting guidelines for oncology RWE studies in peer-reviewed journals "the ESMO Guidance for Reporting Oncology Real-World Evidence (GROW)". To facilitate readers understanding and application of these reporting standards, this article introduces and interprets the development process and main contents of the ESMO-GROW checklist.
The surgical case report（SCARE）statement is the report checklist made by European researchers in 2016, which is specialized for surgical case report. As a reference for enhancing the research quality and transparency, the SCARE statement provides a fundamental framework for surgical case reports. The last SCARE statement was revised in 2020, and this paper interprets it to provide a practical tool for domestic researchers in surgical case report.
ObjectiveTo interpret ROBIS, a new tool to evaluate the risk of bias in systematic reviews, to promote the comprehension of it and its proper application. MethodsWe explained each item of ROBIS tool, used it to evaluate the risk of bias of a selected intervention review whose title was Cyclophosphamide for Primary Nephrotic Syndrome of Children: A Systematic Review, and judged the risk of bias in the review. ResultsThe selected systematic review as a whole was rated as “high risk of bias”, because there existed high risk of bias in domain 2 to 4, namely identification and selection of studies, data collection and study appraisal, synthesis and findings. The risk of bias in domain 1 (study eligibility criteria) was low. The relevance of identified studies and the review’s research question was appropriately considered and the reviewers avoided emphasizing results on the basis of their statistical significance. ConclusionROBIS is a new tool worthy of being recommended to evaluate risk of bias in systematic reviews. Reviewers should use ROBIS items as standards to conduct and produce high quality systematic reviews.
The Universal Definition and Classification of Heart Failure consensus has proposed the universal definition, classification and staging criteria of heart failure. The prevalence of heart failure is still increasing, and the phenotype of heart failure with preserved ejection fraction (HFpEF) is becoming more and more common. Neuro-endocrine antagonists are effective in treating patients with heart failure with reduced ejection fraction (HFrEF). However, there is no effective drug that can improve the clinical prognosis of patients with HFpEF. The pathophysiological mechanism of HFpEF involves metabolic-inflammatory mechanism disorders, epicardial fat tissue accumulation, and coronary microvascular dysfunction. The exploratory treatment of these mechanisms requires further research to confirm whether it is beneficial to patients with HFpEF. In addition, the improvement of ejection fraction and the recovery of cardiac function in patients with HFrEF after treatment cannot interrupt the drug treatment of heart failure.
The development of evidence-based social care guidelines need to follow certain standards and procedures, the process must be objective, fair, and transparent to ensure that guidelines are developed, scientific, timely, and available. Currently, many organizations have issued standard methods for developing guidelines, but the methods are mainly focused on clinical practice, and few methodological studies on the development of social care guidelines. To promote the development of evidence-based social care guidelines in China and strengthen the transformation from research to practice, this article is based on the "Social Care Guidance Manual" published on the NICE website, combined with the actual situation of domestic social care, inviting domestic evidence-based social science research experts to discuss and specifically introduce the development methods of evidence-based social care guidelines, and this article takes the "Guidelines for Providing Social Work Services to Adults with Complex Needs" as an example, interpreting the process for developing guidelines to make the guide development method more transparent.